Central retinal vein thrombosis: Serial treatment with defibrination, aspirin and plasminotropic drugs
A patient with central retinal vein thrombosis was successively treated with defibrination by ancrod for 68 days, reaching a dose of 9360 u/day, then by Defibrase for 50 days to a dose of 40 ml/day; and subsequently with Aspirin for 54 days and then with the plasminotropic drugs phenformin and ethyl...
Gespeichert in:
| Veröffentlicht in: | Thrombosis research 1979, Vol.14 (1), p.61-66 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 66 |
|---|---|
| container_issue | 1 |
| container_start_page | 61 |
| container_title | Thrombosis research |
| container_volume | 14 |
| creator | Gent, A. Ingram, G.I.C. Arocha-Piñango, C.L. Fenton, P. Buckley, R.J. |
| description | A patient with central retinal vein thrombosis was successively treated with defibrination by ancrod for 68 days, reaching a dose of 9360 u/day, then by Defibrase for 50 days to a dose of 40 ml/day; and subsequently with Aspirin for 54 days and then with the plasminotropic drugs phenformin and ethyl oestrenol for 177 days followed by stanozolol for 482 days. None of the treatments appeared to modify the course of the disease, but perhaps they were started too late. However, the large doses of the defibrinating agents were well tolerated, despite evidence for the development of antibodies. Observations were also made on the rate of regeneration of plasma fibrinogen when the defibrination was terminated, and on the shortening of the whole blood clot lysis time during plasminotropic treatment. |
| doi_str_mv | 10.1016/0049-3848(79)90024-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_74514519</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0049384879900240</els_id><sourcerecordid>74514519</sourcerecordid><originalsourceid>FETCH-LOGICAL-e260t-51e9cb2eac114d15cd1fb13eed7ad7c7730ce4f5ae2460acdde9621d71b2dd743</originalsourceid><addsrcrecordid>eNo9UctKBDEQDOJrXf2DPeQkCo4mmcxk40GQxRcseFDPIZP0uJF5mWRW_HuzrggNRXdVN00VQjNKLimh5RUhXGb5nM_PhDyXhDCekR00oXMhM8YF20WTf8khOgrhgxAqqCwO0D5nBZkXE1QvoIteN9hDdF3CNbgOx5Xv26oPLlzjF_AuzaMHHdskxl8urrCF2lU-bUTXdxdYh8GlDuvO4qHRoXVdH30_OIOtH9_DMdqrdRPg5A-n6O3-7nXxmC2fH54Wt8sMWEliVlCQpmKgDaXc0sJYWlc0B7BCW2GEyIkBXhcaGC-JNtaCLBm1glbMWsHzKTrd3h18_zlCiKp1wUDT6A76MSjBC5pKJuHsTzhWLVg1eNdq_622viT6ZktDenbtwKtgHHQGrPNgorK9U5SoTQxq47HaeKyEVL8xKJL_ACoVfD0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>74514519</pqid></control><display><type>article</type><title>Central retinal vein thrombosis: Serial treatment with defibrination, aspirin and plasminotropic drugs</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Gent, A. ; Ingram, G.I.C. ; Arocha-Piñango, C.L. ; Fenton, P. ; Buckley, R.J.</creator><creatorcontrib>Gent, A. ; Ingram, G.I.C. ; Arocha-Piñango, C.L. ; Fenton, P. ; Buckley, R.J.</creatorcontrib><description>A patient with central retinal vein thrombosis was successively treated with defibrination by ancrod for 68 days, reaching a dose of 9360 u/day, then by Defibrase for 50 days to a dose of 40 ml/day; and subsequently with Aspirin for 54 days and then with the plasminotropic drugs phenformin and ethyl oestrenol for 177 days followed by stanozolol for 482 days. None of the treatments appeared to modify the course of the disease, but perhaps they were started too late. However, the large doses of the defibrinating agents were well tolerated, despite evidence for the development of antibodies. Observations were also made on the rate of regeneration of plasma fibrinogen when the defibrination was terminated, and on the shortening of the whole blood clot lysis time during plasminotropic treatment.</description><identifier>ISSN: 0049-3848</identifier><identifier>EISSN: 1879-2472</identifier><identifier>DOI: 10.1016/0049-3848(79)90024-0</identifier><identifier>PMID: 425085</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Aged ; Ancrod - adverse effects ; Ancrod - therapeutic use ; Aspirin - therapeutic use ; Batroxobin - adverse effects ; Batroxobin - therapeutic use ; Ethylestrenol - therapeutic use ; Humans ; Male ; Phenformin - therapeutic use ; Retinal Vein - physiopathology ; Thrombosis - drug therapy</subject><ispartof>Thrombosis research, 1979, Vol.14 (1), p.61-66</ispartof><rights>1979</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0049-3848(79)90024-0$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,4024,27923,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/425085$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gent, A.</creatorcontrib><creatorcontrib>Ingram, G.I.C.</creatorcontrib><creatorcontrib>Arocha-Piñango, C.L.</creatorcontrib><creatorcontrib>Fenton, P.</creatorcontrib><creatorcontrib>Buckley, R.J.</creatorcontrib><title>Central retinal vein thrombosis: Serial treatment with defibrination, aspirin and plasminotropic drugs</title><title>Thrombosis research</title><addtitle>Thromb Res</addtitle><description>A patient with central retinal vein thrombosis was successively treated with defibrination by ancrod for 68 days, reaching a dose of 9360 u/day, then by Defibrase for 50 days to a dose of 40 ml/day; and subsequently with Aspirin for 54 days and then with the plasminotropic drugs phenformin and ethyl oestrenol for 177 days followed by stanozolol for 482 days. None of the treatments appeared to modify the course of the disease, but perhaps they were started too late. However, the large doses of the defibrinating agents were well tolerated, despite evidence for the development of antibodies. Observations were also made on the rate of regeneration of plasma fibrinogen when the defibrination was terminated, and on the shortening of the whole blood clot lysis time during plasminotropic treatment.</description><subject>Aged</subject><subject>Ancrod - adverse effects</subject><subject>Ancrod - therapeutic use</subject><subject>Aspirin - therapeutic use</subject><subject>Batroxobin - adverse effects</subject><subject>Batroxobin - therapeutic use</subject><subject>Ethylestrenol - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Phenformin - therapeutic use</subject><subject>Retinal Vein - physiopathology</subject><subject>Thrombosis - drug therapy</subject><issn>0049-3848</issn><issn>1879-2472</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1979</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UctKBDEQDOJrXf2DPeQkCo4mmcxk40GQxRcseFDPIZP0uJF5mWRW_HuzrggNRXdVN00VQjNKLimh5RUhXGb5nM_PhDyXhDCekR00oXMhM8YF20WTf8khOgrhgxAqqCwO0D5nBZkXE1QvoIteN9hDdF3CNbgOx5Xv26oPLlzjF_AuzaMHHdskxl8urrCF2lU-bUTXdxdYh8GlDuvO4qHRoXVdH30_OIOtH9_DMdqrdRPg5A-n6O3-7nXxmC2fH54Wt8sMWEliVlCQpmKgDaXc0sJYWlc0B7BCW2GEyIkBXhcaGC-JNtaCLBm1glbMWsHzKTrd3h18_zlCiKp1wUDT6A76MSjBC5pKJuHsTzhWLVg1eNdq_622viT6ZktDenbtwKtgHHQGrPNgorK9U5SoTQxq47HaeKyEVL8xKJL_ACoVfD0</recordid><startdate>1979</startdate><enddate>1979</enddate><creator>Gent, A.</creator><creator>Ingram, G.I.C.</creator><creator>Arocha-Piñango, C.L.</creator><creator>Fenton, P.</creator><creator>Buckley, R.J.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>1979</creationdate><title>Central retinal vein thrombosis: Serial treatment with defibrination, aspirin and plasminotropic drugs</title><author>Gent, A. ; Ingram, G.I.C. ; Arocha-Piñango, C.L. ; Fenton, P. ; Buckley, R.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e260t-51e9cb2eac114d15cd1fb13eed7ad7c7730ce4f5ae2460acdde9621d71b2dd743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1979</creationdate><topic>Aged</topic><topic>Ancrod - adverse effects</topic><topic>Ancrod - therapeutic use</topic><topic>Aspirin - therapeutic use</topic><topic>Batroxobin - adverse effects</topic><topic>Batroxobin - therapeutic use</topic><topic>Ethylestrenol - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Phenformin - therapeutic use</topic><topic>Retinal Vein - physiopathology</topic><topic>Thrombosis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gent, A.</creatorcontrib><creatorcontrib>Ingram, G.I.C.</creatorcontrib><creatorcontrib>Arocha-Piñango, C.L.</creatorcontrib><creatorcontrib>Fenton, P.</creatorcontrib><creatorcontrib>Buckley, R.J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Thrombosis research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gent, A.</au><au>Ingram, G.I.C.</au><au>Arocha-Piñango, C.L.</au><au>Fenton, P.</au><au>Buckley, R.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Central retinal vein thrombosis: Serial treatment with defibrination, aspirin and plasminotropic drugs</atitle><jtitle>Thrombosis research</jtitle><addtitle>Thromb Res</addtitle><date>1979</date><risdate>1979</risdate><volume>14</volume><issue>1</issue><spage>61</spage><epage>66</epage><pages>61-66</pages><issn>0049-3848</issn><eissn>1879-2472</eissn><abstract>A patient with central retinal vein thrombosis was successively treated with defibrination by ancrod for 68 days, reaching a dose of 9360 u/day, then by Defibrase for 50 days to a dose of 40 ml/day; and subsequently with Aspirin for 54 days and then with the plasminotropic drugs phenformin and ethyl oestrenol for 177 days followed by stanozolol for 482 days. None of the treatments appeared to modify the course of the disease, but perhaps they were started too late. However, the large doses of the defibrinating agents were well tolerated, despite evidence for the development of antibodies. Observations were also made on the rate of regeneration of plasma fibrinogen when the defibrination was terminated, and on the shortening of the whole blood clot lysis time during plasminotropic treatment.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>425085</pmid><doi>10.1016/0049-3848(79)90024-0</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0049-3848 |
| ispartof | Thrombosis research, 1979, Vol.14 (1), p.61-66 |
| issn | 0049-3848 1879-2472 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_74514519 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Aged Ancrod - adverse effects Ancrod - therapeutic use Aspirin - therapeutic use Batroxobin - adverse effects Batroxobin - therapeutic use Ethylestrenol - therapeutic use Humans Male Phenformin - therapeutic use Retinal Vein - physiopathology Thrombosis - drug therapy |
| title | Central retinal vein thrombosis: Serial treatment with defibrination, aspirin and plasminotropic drugs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A54%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Central%20retinal%20vein%20thrombosis:%20Serial%20treatment%20with%20defibrination,%20aspirin%20and%20plasminotropic%20drugs&rft.jtitle=Thrombosis%20research&rft.au=Gent,%20A.&rft.date=1979&rft.volume=14&rft.issue=1&rft.spage=61&rft.epage=66&rft.pages=61-66&rft.issn=0049-3848&rft.eissn=1879-2472&rft_id=info:doi/10.1016/0049-3848(79)90024-0&rft_dat=%3Cproquest_pubme%3E74514519%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=74514519&rft_id=info:pmid/425085&rft_els_id=0049384879900240&rfr_iscdi=true |